# Asthma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/asthma

> 53 upcoming FDA catalysts in asthma: Fasenra (benralizumab, AZN) on Dec 2026 to Mar 2027 (topline data readout); TEV-56248 (TEVA) on Dec 2026 to Mar 2027 (topline data readout); HFA-152A (GSK) on Dec 2026 to Mar 2027 (topline data readout); Fasenra (benralizumab, AZN) on December 2026 (primary completion); and 49 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 19, 2025 | [Gsk3511294 (depemokimab) primary completion](https://sec-api.dev/pdufa/gsk3511294-depemokimab) | GSK | Asthma | completed | "NCT05243680 (An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-19 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-01-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05243680)) |
| June 4, 2025 | [Intervention: as mdi primary completion](https://sec-api.dev/pdufa/intervention-as-mdi) | AZN | Asthma | completed | "NCT06644924 (A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-04 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-08-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06644924)) |
| September 2, 2025 | [Salbutamol hfa-134a primary completion](https://sec-api.dev/pdufa/salbutamol-hfa-134a) | GSK | Asthma | completed | "NCT06261957 (A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06261957)) |
| September 14, 2025 | [Nucala (mepolizumab) primary completion](https://sec-api.dev/pdufa/mepolizumab) | GSK | Asthma | completed | "NCT04718389 (A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-14 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-05-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04718389)) |
| October 15, 2025 | [Londamocitinib primary completion](https://sec-api.dev/pdufa/londamocitinib) | AZN | Asthma | completed | "NCT06435273 (Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-15 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06435273)) |
| October 28, 2025 | [AZD4604 primary completion](https://sec-api.dev/pdufa/azd4604) | AZN | Asthma | completed | "NCT06020014 (Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06020014)) |
| Q1 2026 | [KT-621 trial start](https://sec-api.dev/pdufa/kt-621) | KYMR | asthma | scheduled | "our expectations regarding strategy, business plans and objectives on the development of KT-621, including the therapeutic potential, clinical benefits and safety thereof, the initiation of the Phase 2b study of KT-621 in patients with asthma in the first quarter of 2026, the effect of initial parallel development of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312525310670/d77337dex991.htm)) |
| January 7, 2026 | [Atuliflapon primary completion](https://sec-api.dev/pdufa/atuliflapon) | AZN | Asthma | completed | "NCT05251259 (Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-07 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05251259)) |
| January 15, 2026 | [Gsk3511294 (depemokimab) topline data readout](https://sec-api.dev/pdufa/gsk3511294-depemokimab) | GSK | Asthma | completed | "NCT05243680 (An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-19 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-01-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05243680?tab=results)) |
| February 4, 2026 | [AZD8630 primary completion](https://sec-api.dev/pdufa/azd8630) | AZN | Asthma | completed | "NCT06529419 (A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-04 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06529419)) |
| February 23, 2026 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Asthma | completed | "NCT06102005 (Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06102005)) |
| April 17, 2026 | [Bda mdi hfo 160/180 μg primary completion](https://sec-api.dev/pdufa/bda-mdi-hfo-160) | AZN | Asthma | completed | "NCT06502366 (A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-17 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06502366)) |
| May 14, 2026 | [Rocatinlimab primary completion](https://sec-api.dev/pdufa/rocatinlimab) | AMGN | Asthma | withdrawn | "NCT06376045 (A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-05-14 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06376045)) |
| May 18, 2026 | [Nucala (mepolizumab) topline data readout](https://sec-api.dev/pdufa/mepolizumab) | GSK | Asthma | completed | "NCT04718389 (A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-14 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-05-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04718389?tab=results)) |
| July 14, 2026 | [GSK5784283 primary completion](https://sec-api.dev/pdufa/gsk5784283) | GSK | Asthma | completed | "NCT06748053 (A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07-14 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06748053)) |
| August 27, 2026 | [Intervention: as mdi topline data readout](https://sec-api.dev/pdufa/intervention-as-mdi) | AZN | Asthma | completed | "NCT06644924 (A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-04 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-08-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06644924?tab=results)) |
| September 22, 2026 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Asthma | withdrawn | "NCT06033833 (Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06033833)) |
| October 6, 2026 | [Salbutamol hfa-134a topline data readout](https://sec-api.dev/pdufa/salbutamol-hfa-134a) | GSK | Asthma | completed | "NCT06261957 (A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06261957?tab=results)) |
| October 26, 2026 | [Fp/abs primary completion](https://sec-api.dev/pdufa/fp-abs) | TEVA | Asthma | completed | "NCT06664619 (A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-26 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06664619)) |
| Oct 2026 to Jan 2027 | [Fp/abs topline data readout](https://sec-api.dev/pdufa/fp-abs) | TEVA | Asthma | scheduled | "NCT06664619 (A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-26 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06664619)) |
| Dec 2026 to Mar 2027 | [Fasenra (benralizumab) topline data readout](https://sec-api.dev/pdufa/benralizumab) | AZN | Asthma | scheduled | "NCT05692180 (A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05692180)) |
| Dec 2026 to Mar 2027 | [TEV-56248 topline data readout](https://sec-api.dev/pdufa/tev-56248) | TEVA | Asthma | scheduled | "NCT06052267 (A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06052267)) |
| Dec 2026 to Mar 2027 | [HFA-152A topline data readout](https://sec-api.dev/pdufa/hfa-152a) | GSK | Asthma | scheduled | "NCT07645248 (A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07645248)) |
| December 2026 | [Fasenra (benralizumab) primary completion](https://sec-api.dev/pdufa/benralizumab) | AZN | Asthma | scheduled | "NCT05692180 (A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05692180)) |
| December 2026 | [HFA-152A primary completion](https://sec-api.dev/pdufa/hfa-152a) | GSK | Asthma | scheduled | "NCT07645248 (A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07645248)) |
| December 2026 | [TEV-56248 primary completion](https://sec-api.dev/pdufa/tev-56248) | TEVA | Asthma | scheduled | "NCT06052267 (A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06052267)) |
| Q1 2027 | [Soquelitinib trial start](https://sec-api.dev/pdufa/soquelitinib) | CRVS | asthma | scheduled | "Corvus plans to initiate a Phase 2 trial evaluating soquelitinib in patients with asthma, by Q1 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184326007175/exh_991.htm)) |
| Jan to Apr 2027 | [Ff/umec/vi topline data readout](https://sec-api.dev/pdufa/ff-umec-vi) | GSK | Asthma | scheduled | "NCT05757102 (A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-26 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05757102)) |
| January 2027 | [Ff/umec/vi primary completion](https://sec-api.dev/pdufa/ff-umec-vi) | GSK | Asthma | scheduled | "NCT05757102 (A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-26 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05757102)) |
| Mar to Jun 2027 | [Pf-07275315 dose 1 topline data readout](https://sec-api.dev/pdufa/pf-07275315) | PFE | Asthma | scheduled | "NCT06977581 (A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06977581)) |
| March 2027 | [Depemokimab primary completion](https://sec-api.dev/pdufa/depemokimab) | GSK | Asthma | scheduled | "NCT07671001 (A Study of Depemokimab in Participants of 6 to 11 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-01 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07671001)) |
| Mar to Jun 2027 | [Depemokimab topline data readout](https://sec-api.dev/pdufa/depemokimab) | GSK | Asthma | scheduled | "NCT07671001 (A Study of Depemokimab in Participants of 6 to 11 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-01 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07671001)) |
| March 2027 | [Pf-07275315 dose 1 primary completion](https://sec-api.dev/pdufa/pf-07275315) | PFE | Asthma | scheduled | "NCT06977581 (A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06977581)) |
| Jun to Sep 2027 | [Lunsekimig topline data readout](https://sec-api.dev/pdufa/lunsekimig) | SNY | Asthma | scheduled | "NCT06676319 (Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-21 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06676319)) |
| Jun to Sep 2027 | [Tozorakimab topline data readout](https://sec-api.dev/pdufa/tozorakimab) | AZN | Asthma | scheduled | "NCT06932263 (Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06-07 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06932263)) |
| June 2027 | [Tozorakimab primary completion](https://sec-api.dev/pdufa/tozorakimab) | AZN | Asthma | scheduled | "NCT06932263 (Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06-07 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06932263)) |
| June 2027 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Asthma | scheduled | "NCT06676319 (Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-21 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06676319)) |
| Jul to Oct 2027 | [Qbrexza (glycopyrronium tosylate) topline data readout](https://sec-api.dev/pdufa/glycopyrronium) | NVS | Asthma | scheduled | "NCT05222529 (Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05222529)) |
| July 2027 | [Qbrexza (glycopyrronium tosylate) primary completion](https://sec-api.dev/pdufa/glycopyrronium) | NVS | Asthma | scheduled | "NCT05222529 (Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05222529)) |
| Oct 2027 to Jan 2028 | [Bda mdi topline data readout](https://sec-api.dev/pdufa/bda-mdi) | AZN | Asthma | scheduled | "NCT06307665 (Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06307665)) |
| Oct 2027 to Jan 2028 | [Budesonide/albuterol metered dose inhaler, mdi topline data readout](https://sec-api.dev/pdufa/budesonide-albuterol-metered-dose-inhaler-mdi) | AZN | Asthma | scheduled | "NCT06471257 (A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06471257)) |
| October 2027 | [Budesonide/albuterol metered dose inhaler, mdi primary completion](https://sec-api.dev/pdufa/budesonide-albuterol-metered-dose-inhaler-mdi) | AZN | Asthma | scheduled | "NCT06471257 (A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06471257)) |
| October 2027 | [Bda mdi primary completion](https://sec-api.dev/pdufa/bda-mdi) | AZN | Asthma | scheduled | "NCT06307665 (Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06307665)) |
| December 2027 | [Aro-rage primary completion](https://sec-api.dev/pdufa/aro-rage) | ARWR | Asthma | scheduled | "NCT07241546 (Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07241546)) |
| Dec 2027 to Mar 2028 | [Aro-rage topline data readout](https://sec-api.dev/pdufa/aro-rage) | ARWR | Asthma | scheduled | "NCT07241546 (Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07241546)) |
| Jan to Apr 2028 | [Depemokimab topline data readout](https://sec-api.dev/pdufa/depemokimab) | GSK | Asthma | scheduled | "NCT06979323 (Depemokimab Asthma Imaging and Bronchoscopy Sub-Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979323)) |
| January 2028 | [Depemokimab primary completion](https://sec-api.dev/pdufa/depemokimab) | GSK | Asthma | scheduled | "NCT06979323 (Depemokimab Asthma Imaging and Bronchoscopy Sub-Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979323)) |
| February 2028 | [QMF149 primary completion](https://sec-api.dev/pdufa/qmf149) | NVS | Asthma | scheduled | "NCT05562466 (A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-01 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05562466)) |
| Feb to May 2028 | [QMF149 topline data readout](https://sec-api.dev/pdufa/qmf149) | NVS | Asthma | scheduled | "NCT05562466 (A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-01 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05562466)) |
| April 2028 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Asthma | scheduled | "NCT07219173 (A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219173)) |
| Apr to Jul 2028 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Asthma | scheduled | "NCT07219173 (A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219173)) |
| May to Aug 2028 | [TEZSPIRE® (tezepelumab) topline data readout](https://sec-api.dev/pdufa/tezepelumab) | AZN | Asthma | scheduled | "NCT06023589 (A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06023589)) |
| May 2028 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Asthma | scheduled | "NCT06023589 (A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06023589)) |
| October 2028 | [WIN378 primary completion](https://sec-api.dev/pdufa/win378) | WWB | Asthma | scheduled | "NCT07120503 (Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10-01 (ESTIMATED); Lead Sponsor Windward Bio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07120503)) |
| Oct 2028 to Jan 2029 | [WIN378 topline data readout](https://sec-api.dev/pdufa/win378) | WWB | Asthma | scheduled | "NCT07120503 (Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10-01 (ESTIMATED); Lead Sponsor Windward Bio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07120503)) |
| Dec 2028 to Mar 2029 | [QVM149 topline data readout](https://sec-api.dev/pdufa/qvm149) | NVS | Asthma | scheduled | "NCT05776927 (A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05776927)) |
| December 2028 | [QVM149 primary completion](https://sec-api.dev/pdufa/qvm149) | NVS | Asthma | scheduled | "NCT05776927 (A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05776927)) |
| Feb to May 2029 | [GSK5784283 topline data readout](https://sec-api.dev/pdufa/gsk5784283) | GSK | Asthma | scheduled | "NCT07780643 (A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-15 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07780643)) |
| February 2029 | [GSK5784283 primary completion](https://sec-api.dev/pdufa/gsk5784283) | GSK | Asthma | scheduled | "NCT07780643 (A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-15 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07780643)) |
| May to Aug 2029 | [Gp mdi topline data readout](https://sec-api.dev/pdufa/gp-mdi) | AZN | Asthma | scheduled | "NCT07525375 (A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07525375)) |
| May to Aug 2029 | [GSK5784283 topline data readout](https://sec-api.dev/pdufa/gsk5784283) | GSK | Asthma | scheduled | "NCT07782996 (A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05-04 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07782996)) |
| May 2029 | [GSK5784283 primary completion](https://sec-api.dev/pdufa/gsk5784283) | GSK | Asthma | scheduled | "NCT07782996 (A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05-04 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07782996)) |
| May 2029 | [Gp mdi primary completion](https://sec-api.dev/pdufa/gp-mdi) | AZN | Asthma | scheduled | "NCT07525375 (A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07525375)) |
| June 2029 | [Tilrekimig primary completion](https://sec-api.dev/pdufa/tilrekimig) | PFE | Asthma | scheduled | "NCT07772921 (A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-01 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07772921)) |
| Jun to Sep 2029 | [Tilrekimig topline data readout](https://sec-api.dev/pdufa/tilrekimig) | PFE | Asthma | scheduled | "NCT07772921 (A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-01 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07772921)) |
| Jun to Sep 2029 | [Tilrekimig topline data readout](https://sec-api.dev/pdufa/tilrekimig) | PFE | Asthma | scheduled | "NCT07869043 (A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-07 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07869043)) |
| June 2029 | [Tilrekimig primary completion](https://sec-api.dev/pdufa/tilrekimig) | PFE | Asthma | scheduled | "NCT07869043 (A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-07 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07869043)) |
| Jul to Oct 2029 | [Bff mdi topline data readout](https://sec-api.dev/pdufa/bff-mdi) | AZN | Asthma | scheduled | "NCT07934420 (An Efficacy and Safety Study to Assess an Inhaled, Fixed-dose, Budesonide/Formoterol Fumarate in Participants Aged 4 to Less Than 12 Years of Age With Moderate Persistent Asthma): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-07-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07934420)) |
| July 2029 | [Bff mdi primary completion](https://sec-api.dev/pdufa/bff-mdi) | AZN | Asthma | scheduled | "NCT07934420 (An Efficacy and Safety Study to Assess an Inhaled, Fixed-dose, Budesonide/Formoterol Fumarate in Participants Aged 4 to Less Than 12 Years of Age With Moderate Persistent Asthma): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-07-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07934420)) |
| Sep to Dec 2029 | [JNJ-95597528 topline data readout](https://sec-api.dev/pdufa/jnj-95597528) | JNJ | Asthma | scheduled | "NCT07746687 (A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-09-11 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07746687)) |
| September 2029 | [JNJ-95597528 primary completion](https://sec-api.dev/pdufa/jnj-95597528) | JNJ | Asthma | scheduled | "NCT07746687 (A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-09-11 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07746687)) |
| Sep to Dec 2030 | [Depemokimab topline data readout](https://sec-api.dev/pdufa/depemokimab) | GSK | Asthma | scheduled | "NCT07456033 (A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07456033)) |
| September 2030 | [Depemokimab primary completion](https://sec-api.dev/pdufa/depemokimab) | GSK | Asthma | scheduled | "NCT07456033 (A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07456033)) |

## Drugs

- [Gsk3511294 (depemokimab)](https://sec-api.dev/pdufa/gsk3511294-depemokimab) (GSK)
- [Intervention: as mdi](https://sec-api.dev/pdufa/intervention-as-mdi) (AZN)
- [Salbutamol hfa-134a](https://sec-api.dev/pdufa/salbutamol-hfa-134a) (GSK)
- [Nucala (mepolizumab)](https://sec-api.dev/pdufa/mepolizumab) (GSK)
- [Londamocitinib](https://sec-api.dev/pdufa/londamocitinib) (AZN)
- [AZD4604](https://sec-api.dev/pdufa/azd4604) (AZN)
- [KT-621](https://sec-api.dev/pdufa/kt-621) (KYMR)
- [Atuliflapon](https://sec-api.dev/pdufa/atuliflapon) (AZN)
- [AZD8630](https://sec-api.dev/pdufa/azd8630) (AZN)
- [Lunsekimig](https://sec-api.dev/pdufa/lunsekimig) (SNY)
- [Bda mdi hfo 160/180 μg](https://sec-api.dev/pdufa/bda-mdi-hfo-160) (AZN)
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab) (AMGN)
- [GSK5784283](https://sec-api.dev/pdufa/gsk5784283) (GSK)
- [Amlitelimab](https://sec-api.dev/pdufa/amlitelimab) (SNY)
- [Fp/abs](https://sec-api.dev/pdufa/fp-abs) (TEVA)
- [Fasenra (benralizumab)](https://sec-api.dev/pdufa/benralizumab) (AZN)
- [TEV-56248](https://sec-api.dev/pdufa/tev-56248) (TEVA)
- [HFA-152A](https://sec-api.dev/pdufa/hfa-152a) (GSK)
- [Soquelitinib](https://sec-api.dev/pdufa/soquelitinib) (CRVS)
- [Ff/umec/vi](https://sec-api.dev/pdufa/ff-umec-vi) (GSK)
- [Pf-07275315 dose 1](https://sec-api.dev/pdufa/pf-07275315) (PFE)
- [Depemokimab](https://sec-api.dev/pdufa/depemokimab) (GSK)
- [Tozorakimab](https://sec-api.dev/pdufa/tozorakimab) (AZN)
- [Qbrexza (glycopyrronium tosylate)](https://sec-api.dev/pdufa/glycopyrronium) (DERM)
- [Bda mdi](https://sec-api.dev/pdufa/bda-mdi) (AZN)
- [Budesonide/albuterol metered dose inhaler, mdi](https://sec-api.dev/pdufa/budesonide-albuterol-metered-dose-inhaler-mdi) (AZN)
- [Aro-rage](https://sec-api.dev/pdufa/aro-rage) (ARWR)
- [QMF149](https://sec-api.dev/pdufa/qmf149) (NVS)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [TEZSPIRE® (tezepelumab)](https://sec-api.dev/pdufa/tezepelumab) (AZN)
- [WIN378](https://sec-api.dev/pdufa/win378) (WWB)
- [QVM149](https://sec-api.dev/pdufa/qvm149) (NVS)
- [Gp mdi](https://sec-api.dev/pdufa/gp-mdi) (AZN)
- [Tilrekimig](https://sec-api.dev/pdufa/tilrekimig) (PFE)
- [Bff mdi](https://sec-api.dev/pdufa/bff-mdi) (AZN)
- [JNJ-95597528](https://sec-api.dev/pdufa/jnj-95597528) (JNJ)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/asthma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Asthma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/asthma

```bibtex
@misc{secapidev_indications_asthma_20261116,
  title        = {Asthma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/asthma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_asthma_20261116","title":"Asthma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/asthma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
